Common and distinct mechanisms of induced pulmonary fibrosis by particulate and soluble chemical fibrogenic agents

Archives of Toxicology

Volumn 90, Issue 2, 2016, Pages 385-402

  Dong, Jie ^a   Yu, Xiaoqing ^b   Porter, Dale W ^a   Battelli, Lori A ^a   Kashon, Michael L ^a   Ma, Qiang ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Bleomycin; Genome wide gene expression; Inflammation; Paraquat; Pulmonary fibrosis; Silica

Indexed keywords

BLEOMYCIN; COLLAGEN; PARAQUAT; SILICON DIOXIDE; PARTICULATE MATTER; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; EXPERIMENTAL PULMONARY FIBROSIS; FIBROGENESIS; GENE EXPRESSION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NASOPHARYNGEAL ASPIRATION; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GENOME; LUNG; LUNG FIBROSIS; METABOLISM; PARTICULATE MATTER; PATHOLOGY; SIGNAL TRANSDUCTION; SOLUBILITY; TOXICITY;

ANIMALS; BLEOMYCIN; GENE EXPRESSION REGULATION; GENOME; LUNG; MALE; MICE, INBRED C57BL; PARAQUAT; PARTICULATE MATTER; PULMONARY FIBROSIS; SIGNAL TRANSDUCTION; SILICON DIOXIDE; SOLUBILITY; TRANSCRIPTION FACTORS;

EID: 84958107676     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-015-1589-3     Document Type: Article

References (48)

1. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57:289–300
2. Berman JS, Serlin D, Li X et al (2004) Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice. Am J Physiol Lung Cell Mol Physiol 286(6):L1311–L1318. doi:10.1152/ajplung.00394.2003
3. Bissonnette E, Rola-Pleszczynski M (1989) Pulmonary inflammation and fibrosis in a murine model of asbestosis and silicosis. Possible role of tumor necrosis factor. Inflammation 13(3):329–339
4. Bus JS, Gibson JE (1984) Paraquat: model for oxidant-initiated toxicity. Environ Health Perspect 55:37–46
5. Carey WA, Taylor GD, Dean WB, Bristow JD (2010) Tenascin-C deficiency attenuates TGF-ss-mediated fibrosis following murine lung injury. Am J Physiol Lung Cell Mol Physiol 299(6):L785–L793. doi:10.1152/ajplung.00385.2009
6. Degryse AL, Lawson WE (2011) Progress toward improving animal models for idiopathic pulmonary fibrosis. Am J Med Sci 341(6):444–449. doi:10.1097/MAJ.0b013e31821aa000
7. Desai B, Mattson J, Paintal H et al (2011) Differential expression of monocyte/macrophage- selective markers in human idiopathic pulmonary fibrosis. Exp Lung Res 37(4):227–238. doi:10.3109/01902148.2010.538132
8. Dinis-Oliveira RJ, Duarte JA, Sanchez-Navarro A, Remiao F, Bastos ML, Carvalho F (2008) Paraquat poisonings: mechanisms of lung toxicity, clinical features, and treatment. Crit Rev Toxicol 38(1):13–71. doi:10.1080/10408440701669959
9. Dong J, Ma Q (2015) Advances in mechanisms and signaling pathways of carbon nanotube toxicity. Nanotoxicology 9:658–676. doi:10.3109/17435390.2015.1009187
10. Dong J, Porter DW, Batteli LA, Wolfarth MG, Richardson DL, Ma Q (2015) Pathologic and molecular profiling of rapid-onset fibrosis and inflammation induced by multi-walled carbon nanotubes. Arch Toxicol 89(4):621–633. doi:10.1007/s00204-014-1428-y
11. Estany S, Vicens-Zygmunt V, Llatjos R et al (2014) Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFbeta1. BMC Pulm Med 14:120. doi:10.1186/1471-2466-14-120
12. Gawarammana IB, Buckley NA (2011) Medical management of paraquat ingestion. Br J Clin Pharmacol 72(5):745–757. doi:10.1111/j.1365-2125.2011.04026.x
13. Giannandrea M, Parks WC (2014) Diverse functions of matrix metalloproteinases during fibrosis. Dis Models Mech 7(2):193–203. doi:10.1242/dmm.012062
14. Haase-Fielitz A, Haase M, Devarajan P (2014) Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem 51(Pt 3):335–351. doi:10.1177/0004563214521795
15. Huang CH, Mirabelli CK, Jan Y, Crooke ST (1981) Single-strand and double-strand deoxyribonucleic acid breaks produced by several bleomycin analogues. Biochemistry 20(2):233–238
16. Huaux F, Liu T, McGarry B, Ullenbruch M, Phan SH (2003) Dual roles of IL-4 in lung injury and fibrosis. J Immunol 170(4):2083–2092
17. Husain AN, Kumar V (2005) The lung. In: Kumar V, Abbas AK, Fausto N (eds) Robbins and Cotran pathologic basis of disease, 7th edn. Elsevier Saunders, Philadelphia, pp 711–772
18. Iqbal N, Choudhary R, Chan J, Wentworth B, Higginbotham E, Maisel AS (2013) Neutrophil gelatinase-associated lipocalin as diagnostic and prognostic tool for cardiovascular disease and heart failure. Expert Opin Med Diagn 7(2):209–220. doi:10.1517/17530059.2013.763795
19. Leung TM, Wang X, Kitamura N, Fiel MI, Nieto N (2013) Osteopontin delays resolution of liver fibrosis. Lab Invest 93(10):1082–1089. doi:10.1038/labinvest.2013.104
20. Lopez MF, Tollervey J, Krastins B et al (2012) Depletion of nuclear histone H2A variants is associated with chronic DNA damage signaling upon drug-evoked senescence of human somatic cells. Aging 4(11):823–842
21. Makris K, Kafkas N (2012) Neutrophil gelatinase-associated lipocalin in acute kidney injury. Adv Clin Chem 58:141–191
22. Matsui Y, Jia N, Okamoto H et al (2004) Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 43(6):1195–1201. doi:10.1161/01.HYP.0000128621.68160.dd
23. McKiernan PJ, McElvaney NG, Greene CM (2011) SLPI and inflammatory lung disease in females. Biochem Soc Trans 39(5):1421–1426. doi:10.1042/BST0391421
24. Meltzer EB, Noble PW (2008) Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 3:8. doi:10.1186/1750-1172-3-8
25. Midwood KS, Hussenet T, Langlois B, Orend G (2011) Advances in tenascin-C biology. Cell Mol Life Sci 68(19):3175–3199. doi:10.1007/s00018-011-0783-6
26. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M (2008) The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40(3):362–382. doi:10.1016/j.biocel.2007.08.011
27. Moore BB, Hogaboam CM (2008) Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294(2):L152–L160. doi:10.1152/ajplung.00313.2007
28. Morgan WKC, Seaton A (1995) Occupational lung diseases, 3rd edn. W.B. Saunders Company, Philadelphia
29. Mori R, Shaw TJ, Martin P (2008) Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med 205(1):43–51. doi:10.1084/jem.20071412
30. NIOSH (2002) Health effects of occupational exposure to respirable crystalline silica. DHHS (NIOSH) Publication No. 2002-129. DHHS CDC NIOSH, Cincinnati, OH
31. Ohtsuka Y, Wang XT, Saito J, Ishida T, Munakata M (2006) Genetic linkage analysis of pulmonary fibrotic response to silica in mice. Eur Respir J 28(5):1013–1019. doi:10.1183/09031936.06.00132505
32. Olson AL, Swigris JJ (2012) Idiopathic pulmonary fibrosis: diagnosis and epidemiology. Clin Chest Med 33(1):41–50. doi:10.1016/j.ccm.2011.12.001
33. Pardo A, Gibson K, Cisneros J et al (2005) Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2(9):e251. doi:10.1371/journal.pmed.0020251
34. Parks CG, Conrad K, Cooper GS (1999) Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 107(Suppl 5):793–802
35. Porter DW, Hubbs AF, Mercer R et al (2004) Progression of lung inflammation and damage in rats after cessation of silica inhalation. Toxicol Sci 79(2):370–380. doi:10.1093/toxsci/kfh110
36. Porter DW, Hubbs AF, Mercer RR et al (2010) Mouse pulmonary dose- and time course-responses induced by exposure to multi-walled carbon nanotubes. Toxicology 269(2–3):136–147. doi:10.1016/j.tox.2009.10.017
37. Rabolli V, Lo Re S, Uwambayinema F, Yakoub Y, Lison D, Huaux F (2011) Lung fibrosis induced by crystalline silica particles is uncoupled from lung inflammation in NMRI mice. Toxicol Lett 203(2):127–134. doi:10.1016/j.toxlet.2011.03.009
38. Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. doi:10.1164/rccm.2009-040GL
39. Rao GV, Tinkle S, Weissman DN et al (2003) Efficacy of a technique for exposing the mouse lung to particles aspirated from the pharynx. J Toxicol Environ Health A 66(15):1441–1452. doi:10.1080/15287390306417
40. Specks U, Nerlich A, Colby TV, Wiest I, Timpl R (1995) Increased expression of type VI collagen in lung fibrosis. Am J Respir Crit Care Med 151(6):1956–1964. doi:10.1164/ajrccm.151.6.7767545
41. Taggart CC, Cryan SA, Weldon S et al (2005) Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 202(12):1659–1668. doi:10.1084/jem.20050768
42. Tan RJ, Fattman CL, Niehouse LM et al (2006) Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice. Am J Respir Cell Mol Biol 35(3):289–297. doi:10.1165/rcmb.2005-0471OC
43. Thomas CR, Kelley TR (2010) A brief review of silicosis in the United States. Environ Health Insights 4:21–26
44. Tounekti O, Pron G, Belehradek J Jr, Mir LM (1993) Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res 53(22):5462–5469
45. Udalova IA, Ruhmann M, Thomson SJ, Midwood KS (2011) Expression and immune function of tenascin-C. Crit Rev Immunol 31(2):115–145
46. Weldon S, Taggart CC (2007) Innate host defense functions of secretory leucoprotease inhibitor. Exp Lung Res 33(10):485–491. doi:10.1080/01902140701756547
47. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18(7):1028–1040. doi:10.1038/nm.2807
48. Zani ML, Tanga A, Saidi A et al (2011) SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions. Biochem Soc Trans 39(5):1441–1446. doi:10.1042/BST0391441